Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kentaro Ito

Showing results (161-170 of 164) with videos related to

Pageof 17
Sort By:
You have reached the last page of results.This site can display upto 164 results.
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
Targeted Oncology|April 13, 2024
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)Naoya Nishioka, Hisao Imai, Masahiro Endo, et al.
Therapeutic Advances in Medical Oncology|June 19, 2025
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring <i>EGFR</i> Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, et al.
JTO Clinical and Research Reports|April 6, 2026
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for <i>EGFR</i> L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED AnalysisMasashi Ishihara, Takahisa Kawamura, Yukiko Namba, et al.
Pageof 17

Showing results (161-170 of 164) with videos related to

Sort By:
Pageof 17
You have reached the last page of results.This site can display upto 164 results.
Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.
Targeted Oncology|April 13, 2024
Real-World Data on Subsequent Therapy for First-Line Osimertinib-Induced Pneumonitis: Safety of EGFR-TKI Rechallenge (Osi-risk Study TORG-TG2101)Naoya Nishioka, Hisao Imai, Masahiro Endo, et al.
Therapeutic Advances in Medical Oncology|June 19, 2025
Ramucirumab and erlotinib combination as first-line treatment for advanced or recurrent non-small cell lung cancer harboring <i>EGFR</i> Exon21 L858R mutation: a multicenter retrospective observational cohort study in Japan (REAL-SPEED)Masashi Ishihara, Takahisa Kawamura, Yukiko Namba, et al.
JTO Clinical and Research Reports|April 6, 2026
Efficacy and Safety of First-Line Ramucirumab Plus Erlotinib for <i>EGFR</i> L858R-Mutated NSCLC in Real-World Practice: A Retrospective Multicenter REAL-SPEED AnalysisMasashi Ishihara, Takahisa Kawamura, Yukiko Namba, et al.
Pageof 17